L. Pare Brunet - 4Scientific Department, Reveal Genomics, S.L

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

A.G. Waks,G. Villacampa,L. Pare Brunet,N.M. Tung, C. Bueno Muiño,I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella Cobo,M. Marín-Aguilera,F. Brasó-Maristany,T. Pascual,O. Martinez Saez,A.C. Wolff,

ESMO Open（2023）

引用0浏览0引用

13P Analytical validation of HER2DX test for early-hER2+ breast cancer

E. Sanfeliu Torres, M. Marín-Aguilera, P. Jares, G. Villacampa, E. Hernández-Illán, B. Gonzalez-Farre, F. Brasó-Maristany, P. Galván,O. Castillo, P. Blasco, V. Sirenko, Á. Aguirre,

ESMO Open（2023）

引用0浏览0引用

149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study

N. Gomez Serra, F. Brasó-Maristany, B. Fullana Grimalt,R. Ortega, A. Petit,M. Vicente, C. Falo, A. Stradella, M. Bañuls,L. Pare Brunet, M. Marín-Aguilera, A. Fernandez Ortega,

Annals of Oncology（2023）

引用0浏览0引用

8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

O. Martinez Saez, F. Brasó-Maristany, M. Marín-Aguilera,M.J. Vidal Losada, B. Adamo, T. Pascual, F. Schettini,B. Conte, N. Chic,R. Gomez Bravo, I. Garcia Fructuoso,E. Segui Solis,

ESMO Openno. 1 (2023): 101232-101232

引用0浏览0引用

150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial

A. Llombart Cussac,J.M. Pérez-García,L. Pare Brunet,G. Villacampa Javierre, F. Brasó-Maristany,M. Gion Cortes,P. Schmid, M.A. Colleoni,M. Ruiz Borrego, P. Galván, J. Parker,C.M. Perou,

Annals of Oncology (2023): S240-S241

引用0浏览0引用

5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis

O. Martinez Saez, F. Brasó-Maristany, G. Griguolo,L. Pare Brunet,M.V. Dieci,J. Cortés,A. Llombart Cussac, G. Villacampa, M. Marín-Aguilera,M. Rey, G. Goberna,M. Munoz,

ESMO Openno. 1 (2023): 101229-101229

引用0浏览0引用

12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial

F. Lynce, F. Brasó-Maristany, A.G. Waks,P. Villagrasa Gonzalez, G. Villacampa,E. Sanfeliu Torres, P. Galván,L. Pare Brunet, L. Anderson,C.M. Perou, J. Parker, A. Vivancos,

ESMO Openno. 1 (2023): 101236-101236

引用0浏览0引用

102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset

T. Pascual,G. Villacampa, F. Brasó-Maristany,L. Pare Brunet,O. Martinez Saez,J. Cortés, E.M. Ciruelos,M. Martin Jimenez, P.F. Conte, L.A. Carey, A. Fernandez-Martinez, N. Harbeck,

ESMO Open（2023）

引用0浏览0引用

11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study

B. Fullana Grimalt, F. Brasó-Maristany, N. Gómez, A. Petit,R. Ortega,M. Vicente, C. Falo, A. Stradella,S. Vazquez,R. Villanueva Vazquez, M.J. Pla, E. Purqueras,

ESMO Open（2023）

引用0浏览0引用

6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials

P. Tarantino, G. Villacampa, N. Graham, A.G. Waks,P. Villagrasa Gonzalez, F. Brasó-Maristany,E. Sanfeliu Torres, P. Galván,L. Pare Brunet, M.K. Demeo, A.H. Partridge, H.J. Burstein,

ESMO Openno. 1 (2023): 101230-101230

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn